Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
نویسندگان
چکیده
BCC: Basal cell carcinoma INTRODUCTION The case of a 65-year-oldwomanwith an advanced, ulcerated biopsy-proven basal cell carcinoma (BCC) located on the left side of her upper back is reviewed. She was treated with vismodegib with only mild clinical improvement. Pathologic analysis of subsequent surgical resection found only granulation tissue with no evidence of residual tumor. It is important for clinicians to be aware that gross disease may not correlate with microscopic disease after treatment with vismodegib.
منابع مشابه
Rapid response to vismodegib in a patient with advanced basal cell carcinoma
BCC: Basal cell carcinoma INTRODUCTION Basal cell carcinoma (BCC) is the most common form of skin cancer, making up approximately 80% of all nonmelanoma skin cancers. Traditional therapy includes various types of surgery (Mohs, cryosurgery, excision, electrodessication and curettage), topical therapies (5-fluorouracil, imiquimod), or radiation therapy. A new and effective treatment, vismodegib,...
متن کاملParotid Gland Carcinoma Masquerading as an Aural Polyp
Introduction Parotid gland squamous cell carcinoma is an uncommon aggressive neoplasm with poor prognosis. Aural polyps are usually the presenting features of chronic suppurative otitis media, tuberculous otitis media, and adenoma or carcinoma. The malignant aural polyp is very rare. Parotid gland carcinoma masquerading as an aural polyp has rarely been described in the literature. ...
متن کاملEmergence of Squamous Cell Carcinoma during Treatment of Basal Cell Carcinoma with Vismodegib
Basal cell carcinoma (BCC) accounts for 80% of all non-melanoma skin cancer [1]. Advanced disease is infrequently seen, but when present can be a surgical challenge or even life threatening. Recent studies show that mutations in the hedgehog (HH) signaling pathway are associated with the majority of BCC. Hedgehog protein binds to patched homologue 1 (PTCH1) transmembrane receptor, which prevent...
متن کاملRole of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma.
BACKGROUND Vismodegib is the first selective hedgehog pathway inhibitor approved to treat locally advanced and metastatic basal cell carcinoma (BCC). Limited information is available concerning its role in managing advanced BCC around the eye. METHODS The medical literature was searched for cases of nonsyndromic periocular BCC treated with vismodegib. Clinical information was abstracted and a...
متن کاملVismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
IMPORTANCE Immunosuppressed patients with solid organ transplants have an increased risk for nonmelanoma skin cancer. Vismodegib has been reported to be effective for select locally advanced or metastatic basal cell carcinomas. However, there is no data documenting the use and safety of vismodegib in immunosuppressed organ transplant patients. OBSERVATIONS We describe a 78-year-old white man ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2018